昭衍新药(06127)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06127 昭衍新药

休市中 07-24 16:08:05

24.460

-0.580

-2.32%

最高25.900	最低24.140	成交量578.93万
今开25.580	昨收25.040	日振幅7.03%
总市值183.21亿	流通市值29.11亿	总股本7.49亿
成交额1.44亿	换手率4.87%	流通股本1.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06127","market":"HK","secType":"STK","nameCN":"昭衍新药","latestPrice":24.46,"timestamp":1784880485006,"preClose":25.04,"halted":0,"volume":5789331,"delay":0,"changeRate":-0.023162939297124534,"floatShares":118995206,"shares":749000000,"eps":0.4630477743969385,"marketStatus":"休市中","change":-0.58,"latestTime":"07-24 16:08:05","open":25.58,"high":25.9,"low":24.14,"amount":143535028,"amplitude":0.070288,"askPrice":24.46,"askSize":36500,"bidPrice":24.38,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":0.790258168935663,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":7,"adr":0,"listingDate":1614268800000,"exchange":"SEHK","adjPreClose":25.04,"dividendRate":0.005676,"openAndCloseTimeList":[[1784856600000,1784865600000],[1784869200000,1784880000000]],"volumeRatio":0.4029898957288221,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"603127","market":"SH","secType":"STK","nameCN":"昭衍新药","latestPrice":45.26,"timestamp":1784876400000,"preClose":48.49,"halted":0,"volume":56116800,"delay":0,"premium":"-53.32"}},"requestUrl":"/m/hq/s/06127","defaultTab":"news","newsList":[{"id":"2653770707","title":"7月24日昭衍新药跌6.66%，广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653770707","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653770707?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:37","pubTimestamp":1784882276,"startTime":"0","endTime":"0","summary":"证券之星消息，7月24日昭衍新药跌6.66%，收盘报45.26元，换手率8.94%，成交量56.12万手，成交额25.97亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共40家，其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为35.24亿元，最新净值1.9034，较上一交易日上涨0.6%，近一年下跌7.51%。广发医疗保健股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","BK0216","BK1141","06127","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653726691","title":"昭衍新药（603127）披露2026年A股限制性股票激励计划授予结果公告，7月23日股价上涨0.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653726691","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653726691?lang=zh_cn&edition=full","pubTime":"2026-07-23 22:10","pubTimestamp":1784815828,"startTime":"0","endTime":"0","summary":"截至2026年7月23日收盘，昭衍新药报收于48.49元，较前一交易日上涨0.89%，最新总市值为363.36亿元。近日，北京昭衍新药研究中心股份有限公司披露《2026年A股限制性股票激励计划授予结果公告》。公告显示，公司完成2026年A股限制性股票激励计划授予登记，登记日为2026年7月22日，实际授予238名激励对象263.6300万股，授予价格19.05元/股，股票来源为二级市场回购股份。激励成本合计约3,756.73万元，将在2026年至2029年期间分期摊销。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300047921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK1141","BK0216","399300","06127","159982","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114909623","title":"昭衍新药（06127）完成263.63万股限制性股票授予","url":"https://stock-news.laohu8.com/highlight/detail?id=1114909623","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114909623?lang=zh_cn&edition=full","pubTime":"2026-07-23 17:41","pubTimestamp":1784799681,"startTime":"0","endTime":"0","summary":"2026年7月24日，北京昭衍新药研究中心股份有限公司披露2026年A股限制性股票激励计划授予结果。根据公告，公司已于2026年7月22日在中国证券登记结算有限责任公司上海分公司完成限制性股票授予登记，实际授予数量263.63万股，授予对象238人。公司此前计划授予316.23万股限制性股票；在缴款过程中，42名激励对象因个人原因放弃52.60万股，最终授予数量调整为263.63万股。公告称，本次限制性股票授予完成后，公司将按计划推进后续解锁及回购注销工作。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126533849","title":"异动解读｜昭衍新药盘中上涨5.35%，巴克莱增持叠加CXO板块持续走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1126533849","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126533849?lang=zh_cn&edition=full","pubTime":"2026-07-23 09:47","pubTimestamp":1784771246,"startTime":"0","endTime":"0","summary":"7月23日，昭衍新药盘中上涨5.35%，报26.4港元，成交额5961.45万港元。消息面上，港交所权益披露显示，巴克莱银行于7月15日增持昭衍新药约327.98万股，每股作价约24.25港元，总金额约7954万港元，增持后持股比例升至6.12%。此外，生命科学工具和服务板块整体延续反弹趋势，同行业英矽智能涨5.63%、金斯瑞生物科技涨2.3%、药明生物涨2.16%、药明康德涨1.85%，板块景气度持续回暖为股价提供支撑。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读｜昭衍新药盘中上涨5.35%，巴克莱增持叠加CXO板块持续走强","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120356531","title":"异动解读｜昭衍新药盘中上涨5.08%，巴克莱增持叠加CXO板块持续走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1120356531","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120356531?lang=zh_cn&edition=full","pubTime":"2026-07-22 09:54","pubTimestamp":1784685286,"startTime":"0","endTime":"0","summary":"7月22日，昭衍新药盘中上涨5.08%，报26.06港元，成交额1.04亿港元。消息面上，港交所权益披露显示，巴克莱银行于7月15日增持昭衍新药约327.98万股，每股作价约24.25港元，总金额约7954万港元，增持后持股比例升至6.12%。此外，CXO板块整体延续反弹趋势，同行业药明康德涨3.47%、康龙化成涨6.52%、药明生物涨2.73%，板块景气度持续回暖为股价提供支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读｜昭衍新药盘中上涨5.08%，巴克莱增持叠加CXO板块持续走强","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115645076","title":"异动解读｜昭衍新药盘中上涨6.62%，巴克莱增持叠加CXO板块延续反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1115645076","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115645076?lang=zh_cn&edition=full","pubTime":"2026-07-21 13:17","pubTimestamp":1784611064,"startTime":"0","endTime":"0","summary":"7月21日，昭衍新药盘中上涨6.62%，报25.12港元，成交额2.02亿港元。消息面上，港交所最新权益披露显示，巴克莱银行于7月15日增持昭衍新药约327.98万股，每股作价约24.25港元，总金额约7954万港元，增持后持股比例升至6.12%。此外，CXO板块整体延续反弹趋势，药明生物、药明康德等同行业个股同日普涨，板块景气度回暖为股价提供支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652821977","title":"昭衍新药（603127）披露完成股份性质变更暨2026年A股限制性股票激励计划实施进展，7月20日股价下跌1.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652821977","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652821977?lang=zh_cn&edition=full","pubTime":"2026-07-20 22:04","pubTimestamp":1784556262,"startTime":"0","endTime":"0","summary":"截至2026年7月20日收盘，昭衍新药报收于47.0元，较前一交易日下跌1.94%，最新总市值为352.19亿元。近日，昭衍新药发布《关于完成股份性质变更暨2026年A股限制性股票激励计划实施的进展公告》。公告显示，公司已完成2026年A股限制性股票激励计划授予登记，实际向238名激励对象授予263.6300万股限制性股票，授予价格为19.05元/股，认购款总计50,221,515.00元。股份来源为公司从二级市场回购的A股普通股股票，相关股份已由无限售条件流通股变更为有限售条件流通股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000039186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK0216","399300","BK1141","06127","159982","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652890218","title":"Barclays PLC增持昭衍新药(06127)约327.98万股 每股作价约24.25港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652890218","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652890218?lang=zh_cn&edition=full","pubTime":"2026-07-20 19:32","pubTimestamp":1784547178,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，7月15日，Barclays PLC增持昭衍新药327.982万股，每股作价24.2508港元，总金额约为7953.83万港元。增持后最新持股数目约为728.53万股，最新持股比例为6.12%。补充资料：Notifiable interest first occurred due to increase in Equity shares. BBPLCs interests in 2068664 shares long and short and BCSLs interests in 1295444 shares long and 773220 shares short as disclosed at box 22 pertain to an intragroup hedge between BBPLC and BCSL. Interests arising under the hedge are not double counted at BPLCs level.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469911.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","BK1576","BK1141","EWH","06127","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176246476","title":"昭衍新药（06127）完成股份性质变更并落实2026年限制性股票授予","url":"https://stock-news.laohu8.com/highlight/detail?id=1176246476","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176246476?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:06","pubTimestamp":1784541964,"startTime":"0","endTime":"0","summary":"北京昭衍新药研究中心股份有限公司7月21日公告，其2026年A股限制性股票激励计划已完成股份性质变更及相关登记手续。公告显示，因2025年年度A股权益分派影响，公司将授予价格由19.17元/股调整为19.05元/股。上述股份由公司回购的A股普通股转换而来，已由无限售条件流通股变更为有限售条件流通股。公司称，后续将继续推进限制性股票的登记工作，并按规定及时披露进展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652329383","title":"当一家CRO的利润由实验猴重估，账面繁荣为何盖不住主业失血","url":"https://stock-news.laohu8.com/highlight/detail?id=2652329383","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652329383?lang=zh_cn&edition=full","pubTime":"2026-07-20 15:18","pubTimestamp":1784531905,"startTime":"0","endTime":"0","summary":"2026年7月中旬，国内药物非临床CRO龙头企业昭衍新药（603127.SH/06127.HK）成为资本市场焦点。7月14日晚间，公司发布半年度业绩预告，预计上半年实现归母净利润6亿元至9亿元，同比暴增884.9%至1377.4%，远超市场预期。受此消息刺激，公司股价连续三个交易日涨幅偏离值累计超过20%，触发交易异常波动公告。7月17日，开盘11分钟触及跌停。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607203813239470.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607203813239470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["603127","BK0216","06127","BK1576","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106056395","title":"异动解读｜昭衍新药盘中上涨6.9%，半年报预增近14倍叠加CXO板块持续走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1106056395","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106056395?lang=zh_cn&edition=full","pubTime":"2026-07-20 10:03","pubTimestamp":1784512983,"startTime":"0","endTime":"0","summary":"7月20日，昭衍新药盘中上涨6.9%，报24.86港元，成交额1.94亿港元。消息面上，公司此前披露上半年业绩预告，预计归母净利润约6亿元至9亿元，同比增长884.9%至1,377.4%，其中生物资产公允价值变动贡献净利润约7.03亿元至7.77亿元，主因实验猴市场价格突破20万元叠加自然生长增值。同时CXO板块整体延续反弹趋势，同行业药明生物、康龙化成、药明合联等今日普涨，板块景气度回暖为股价提供支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652126699","title":"CRO概念板块短线走低，灵康药业、昭衍新药、美诺华跌停","url":"https://stock-news.laohu8.com/highlight/detail?id=2652126699","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652126699?lang=zh_cn&edition=full","pubTime":"2026-07-20 09:39","pubTimestamp":1784511595,"startTime":"0","endTime":"0","summary":"7月20日，CRO概念板块短线走低，灵康药业、昭衍新药、美诺华跌停，万邦医药、百奥赛图、百花医药、峆一药业、双成药业等跟跌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607203812244470.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607203812244470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["603538","603669","BK0033","BK0216","BK0239","603127","BK0056","BK1576","BK1141","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652323753","title":"每周股票复盘：昭衍新药（603127）上半年净利预增884.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652323753","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652323753?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:10","pubTimestamp":1784394618,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，昭衍新药报收于47.93元，较上周的43.22元上涨10.9%。本周关注点来自交易信息汇总：昭衍新药因股价涨幅偏离值累计超20%及日振幅达15%两度登上龙虎榜。来自业绩披露要点：昭衍新药预计2026年上半年归母净利润同比增长884.9%至1,377.4%。昭衍新药因有价格涨跌幅限制的日价格振幅达到15%的前五只证券，于2026年7月14日首次登上龙虎榜。公司股票于2026年7月14日至7月16日连续三个交易日内收盘价格涨幅偏离值累计超过20%，构成交易异常波动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","06127","BK1576","BK0216","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115034759","title":"昭衍新药（06127）调整公司秘书及授权代表人事安排","url":"https://stock-news.laohu8.com/highlight/detail?id=1115034759","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115034759?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:55","pubTimestamp":1784282151,"startTime":"0","endTime":"0","summary":"北京昭衍新药研究中心股份有限公司7月17日发布公告称，公司管理层进行人事调整，自2026年7月17日起生效。调整后，公司授权代表为冯宇霞女士及李晶莹女士，法律程序文件代理人为何咏紫女士及李晶莹女士。董事会对张嘉伦女士的贡献表示感谢，并欢迎李晶莹女士出任新职。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158577693","title":"昭衍新药(06127)调整联席公司秘书和授权代表 李晶莹7月17日接任","url":"https://stock-news.laohu8.com/highlight/detail?id=1158577693","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158577693?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:55","pubTimestamp":1784282139,"startTime":"0","endTime":"0","summary":"北京昭衍新药研究中心股份有限公司(06127)7月18日公告称，公司已于2026年7月17日召开第五届董事会第六次会议，审议并通过《关于变更联席公司秘书、授权代表及法律程序文件代理人的议案》。会议应出席董事11人，实际出席11人，以11票赞成、0票反对、0票弃权的结果通过该议案。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652940101","title":"昭衍新药(06127)：李晶莹获委任为联席公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2652940101","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652940101?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:51","pubTimestamp":1784281886,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昭衍新药(06127)发布公告，由于个人工作安排，张嘉伦女士(张女士)已辞任本公司联席公司秘书一职，并不再担任香港联合交易所有限公司(联交所)证券上市规则(上市规则)第 3.05条项下的本公司授权代表(授权代表)，以及上市规则第19A.13(2)条及公司条例(香港法例第622章)第16部项下所规定代表本公司于香港接收法律程序文件及通知的本公司授权代表(法律程序文件代理人)，自2026年7月17日起生效。继张女士辞任后，董事会宣布，李晶莹女士(李女士)已获委任为本公司的联席公司秘书，自2026年7月17日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06127","BK1141","BK1576","BK0216","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168059671","title":"一周港股牛熊榜 | 真健康医疗-B受手术机器人题材催化爆升74%，卓越睿新牵手阿里云涨逾40%；德适-B高估值回调近37%，钧达股份预亏拖累跌逾34%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168059671","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168059671?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:24","pubTimestamp":1784280294,"startTime":"0","endTime":"0","summary":"总结全周（7月13日-7月17日），恒生指数涨387.12点或1.6%，恒生科技指数跌98.49点或2.09%。本周涨幅居前个股中，真健康医疗-B受手术机器人稀缺性及高端医疗器械政策催化，累计上涨74%；卓越睿新与阿里云合作推进AI教学及科研场景落地，本周上涨40.03%；维立志博-B因六项研究入选ESMO、核心管线进入优先审评，累计上涨29.21%。跌幅方面，德适-B在高估值及持续亏损压力下累计下跌36.94%；钧达股份预告上半年最高亏损2.7亿元，累计下跌34.83%；建滔积层板在PCB涨价线高位回落下累计下跌33.15%。","market":"hk","thumbnail":"https://static.tigerbbs.com/cb1639b5fc4982ccb82111d6af456d9b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/cb1639b5fc4982ccb82111d6af456d9b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02865","02687","02697","01888","06127","03277","02889","BK4588","09887","00148","02526"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2652247033","title":"上蹿下跳的“猴茅”，开盘11分钟跌停","url":"https://stock-news.laohu8.com/highlight/detail?id=2652247033","media":"华夏时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652247033?lang=zh_cn&edition=full","pubTime":"2026-07-17 14:17","pubTimestamp":1784269020,"startTime":"0","endTime":"0","summary":"“猴茅”昭衍新药（603127）近日爆火，股价在短短一周内，先后经历了两个涨停板。然而，今日（7月17日）开盘后，A股股价很快就趴在了跌停板上。截至发稿，股价仍跌停，昭衍新药（603127）报47.93元/股，最新市值359.2亿元。港股也一度跌超10%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607173810964476.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607173810964476.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1141","BK1576","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137672236","title":"港股直击 | 昭衍新药盘中跌超10%，公司紧急提示：存非理性炒作风险","url":"https://stock-news.laohu8.com/highlight/detail?id=1137672236","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137672236?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:04","pubTimestamp":1784253885,"startTime":"0","endTime":"0","summary":"$昭衍新药(06127)$ 跌超10%，截至发稿，跌10.15%，报23.22港元，成交额2.01亿港元。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652769614","title":"港股异动 | 昭衍新药(06127.HK)再跌超11% 公司发布风险提示公告 实验猴涨价贡献绝大多数纯利","url":"https://stock-news.laohu8.com/highlight/detail?id=2652769614","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652769614?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:01","pubTimestamp":1784253703,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06127","BK1576","BK1141"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0295},{"period":"1month","weight":0.4271},{"period":"3month","weight":0.1146},{"period":"6month","weight":-0.0392},{"period":"1year","weight":0.0813},{"period":"ytd","weight":0.1968}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0662},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0668},{"period":"1year","weight":-0.0274},{"period":"ytd","weight":-0.026}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"北京昭衍新药研究中心股份有限公司是一家主要从事新药药理毒理学研究的中国公司。该公司通过三个分部开展业务。药物非临床研究服务分部主要提供药品非临床安全性评价服务、药效学研究服务、药代动力学研究服务。临床服务及其他分部主要提供药品上市前的临床服务以及药物警戒服务。实验模型供应分部为实验模型及其附属产品的生产和销售。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.052852},{"month":2,"riseRate":0.6,"avgChangeRate":0.086368},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.020373},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.07562},{"month":5,"riseRate":0.666667,"avgChangeRate":0.065576},{"month":6,"riseRate":0.666667,"avgChangeRate":0.063039},{"month":7,"riseRate":0.833333,"avgChangeRate":0.139575},{"month":8,"riseRate":0,"avgChangeRate":-0.152528},{"month":9,"riseRate":0.6,"avgChangeRate":0.01621},{"month":10,"riseRate":0.2,"avgChangeRate":-0.062964},{"month":11,"riseRate":0.4,"avgChangeRate":0.019565},{"month":12,"riseRate":0.6,"avgChangeRate":0.001933}],"exchange":"SEHK","name":"昭衍新药","nameEN":"JOINN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昭衍新药(06127)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昭衍新药(06127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昭衍新药,06127,昭衍新药股票,昭衍新药股票老虎,昭衍新药股票老虎国际,昭衍新药行情,昭衍新药股票行情,昭衍新药股价,昭衍新药股市,昭衍新药股票价格,昭衍新药股票交易,昭衍新药股票购买,昭衍新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昭衍新药(06127)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昭衍新药(06127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}